Graduate Research Assistant
University of Houston
Olajumoke Olateju, BPharm, MS, PhD, is a health economics and outcomes research (HEOR) scientist and pharmacist with expertise in substance use disorder (SUD), oncology, and medication safety. She is a PhD-trained researcher specializing in real-world evidence, causal inference, and health policy evaluation, with a strong focus on buprenorphine treatment initiation, adherence, and clinical and economic outcomes among patients with opioid use disorder.
Dr. Olateju’s work leverages large administrative claims and registry data, including Medicare and commercial datasets, to evaluate treatment trajectories, overdose risk, healthcare utilization, and costs. Her research emphasizes clinically meaningful outcomes and policy-relevant evidence to inform treatment guidelines, payer decision-making, and quality improvement efforts. She has published extensively in peer-reviewed journals and presented her work at national conferences.
Dr. Olateju currently works in oncology HEOR in industry and collaborates with academic and policy partners to advance evidence-based strategies that improve access to effective, safe, and equitable care for individuals with substance use disorders.
